GLIPIQ
by Glenmark Pharmaceuticals · DCGI approved March 2026
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| DCGI status | Approved March 2026 |
| Price (MRP) | ₹325–440/week Vial-format pricing per weekly dose; pen format priced higher |
| Format | Vial + Prefilled pen |
| Prescription | Schedule H — required |
How GLIPIQ compares
GLIPIQ is Glenmark's generic semaglutide for type 2 diabetes, available in both multi-dose vial and prefilled pen formats. Glenmark's positioning is value pricing on the vial format — at ₹325–440 per weekly dose, GLIPIQ vials sit in the middle of the Indian generic price band, undercutting branded pen products while staying above Eris/Natco's SUNDAE entry price.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is one of India's top-ten pharma companies with a global respiratory and dermatology franchise. The GLIPIQ launch positions Glenmark in the cardiometabolic space for the first time at scale.
Manufacturer announcement
Additional source
Pearce IP — generic semaglutide India launchesGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.